Skip to main
  1. Stocks
  2. Adagene
  3. Forecast
ADAG

Adagene (ADAG) Stock Forecast & Price Target

Adagene (ADAG) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adagene is compelling fundamentally because its SAFEbody platform appears to expand the therapeutic window of CTLA-4 and T-cell engager biology, enabling high-dose immune activation with potentially better tolerability than unmasked antibodies. The case is strengthened by muzastotug’s encouraging Phase 1b signals, where management attributes the rising response rate to dose, plus supportive HCC triplet data showing 66.7% ORR versus 32.5% for control and no clear high-grade toxicity penalty. Beyond clinical data, the company has meaningful optionality from partnerships and cash support, including a $2.0M Exelixis milestone, Third Arc funding of development, and an extended runway into 2H28.

Bears say

Adagene is exposed to significant clinical-risk because ADG126’s encouraging 36% ORR comes from only n=14 in small, non-randomized cohorts, with no monotherapy or pembrolizumab-only control to isolate its contribution. The safety profile remains concerning, as grade 3 TRAEs reached 50% and grade 3 diarrhea/colitis 29%, while prior masked CTLA-4 programs have shown mixed or disappointing results in MSS CRC, where single-arm signals often fade in randomized testing. Financially, the company’s ~$122M net cash appears insufficient for registrational-scale metastatic and potential neoadjuvant development, increasing the likelihood of additional financing, dilution, or dependence on partnering amid regulatory and China-related execution risks.

Adagene (ADAG) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adagene and is not a guaranteed prediction by Public.com or investment advice.

Adagene (ADAG) Analyst Forecast & Price Prediction

Get the latest Adagene (ADAG) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Adagene (ADAG)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adagene (ADAG) Forecast

Analysts have given Adagene (ADAG) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Adagene (ADAG) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adagene (ADAG)


Adagene (ADAG) Analyst Forecast & Price Prediction

Get the latest Adagene (ADAG) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Adagene (ADAG)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ADAG stock data and trends